



Acobiom and UW Carbone Cancer Center collaborate to develop precision medicine approach in pancreatic cancer treatment

Montpellier, France, June 07, 2018 - Acobiom, a company specialized in the discovery of biological markers and in the development of innovative Diagnostics in Precision Medicine, is pleased to announce a collaborative agreement with the University of Wisconsin's Carbone Cancer Center (UWCCC, Madison, Wisconsin, USA). This partnership aims to develop Precision Medicine approach in the field of pancreatic adenocarcinoma treatment.

Pancreatic cancer became the third leading cause of cancer-related death in the United States in 2017, and it is anticipated to become the second around 2020 (source: Pancan & American Cancer Society Cancer Facts & Figures 2018). The number of new cases per year is still increasing and should reach 142,000 new cases in 2020 in Europe+USA (source: IARC/Globocan).

For 80% of patients diagnosed with pancreatic cancer with unresectable tumors, chemotherapy is the only first therapeutic option. As few patients survive beyond five years, doctors describe the situation as "a race against time": they must quickly choose the drug regimen that will be the most effective.

The Acobiom-UWCCC collaboration focuses on the Acobiom's GemciTest[®], a predictive diagnostic blood test enabling the identification of patients who are most likely to benefit from gemcitabine. This blood test aims to support physician decision making and adjusting treatment practices in pancreatic cancer. GemciTest[®] will benefit patients by avoiding therapies that would have strong side effects, resulting in a lower quality of life during their treatment, and a shorter survival in some cases.

Acobiom's co-founder and CEO, Didier Ritter, says "this collaboration with the University of Wisconsin's Carbone Cancer Center provides our French company the opportunity to develop a clinically-compatible diagnostic test to improve quality of life and overall survival for patients suffering from pancreatic adenocarcinoma by predicting their response to gemcitabine." In this partnership, Dr. Noelle LoConte, Associate Professor of Medicine at the University of Wisconsin, will provide her clinical and research expertise within the oncology field along with blood samples from patients with pancreatic adenocarcinoma.

"An international study that follows FDA recommendations is a prerequisite before commercializing GemciTest[®] on US market", adds Didier Ritter. The development of precision medicine therapies in pancreatic cancer is a major focus to improve both patient quality of life during treatment and for their overall survival. The development of diagnostic solutions, as predictive diagnostic blood tests, may be one of the most accurate ways to adjust treatments modalities for patients with pancreatic cancer.

GemciTest[®] will also be commercialized in Europe market after its CE mark clearance.

ACOBBIOM

1682, rue de la Valsière - CS77394 - Cap Delta - Biopole Euromedecine II - 34184 Montpellier Cedex 4 - France
Tel.: +33 (0)467 419 748 - Fax: +33 (0)467 457 726 - Email: busdev@acobiom.com - Web: www.acobiom.com

About UW Carbone Cancer Center: www.uwhealth.org/cancer

The University of Wisconsin Carbone Cancer Center is deeply committed to beating cancer through research, prevention, and treatment. UWCCC's goal is to encourage greater and wider participation in cancer research and care at the University and in the State of Wisconsin, with an ultimate goal of dramatically reducing the burden of cancer on its patients and communities.

The UW Carbone Cancer Center (UWCCC) holds the unique distinction of being the only comprehensive cancer center in Wisconsin, as designated by the National Cancer Institute, the lead federal agency for cancer research. An integral part of the UW School of Medicine and Public Health, the UWCCC unites physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit cancer patients. More than 30,000 people are seen annually for diagnosis, therapy, follow-up care or consultations at UW Hospital and Clinics, as well as our other clinical locations.

Contact: Everlyne Nkadori (nkadori@wisc.edu)

About Acobiom: www.acobiom.com

Acobiom is a biotechnology company specialized in the discovery of new biological markers and the development of innovative diagnostics focused on Precision Medicine or Personalized Medicine. Precision medicine is meeting patients' needs: adapting treatments to patient biological profiles, reducing drug side effects, better managing health expenditures and offering better therapeutic efficacy. Biological markers are identified and selected by Acobiom using its proprietary technological platform, which combines genomics, transcriptomics, bioinformatics, and data science. With its unique scientific expertise in analyzing gene expression in blood cells and whole blood, Acobiom has established its position in the field of Precision Medicine and in the development of diagnostics in order to select the best-in-class treatment. This approach enables targeted drug selection that matches the patient's own phenotypic profile for the treatment of diseases. Founded in 1999, Acobiom is located in the Biopole Euromedicine life sciences business center in Montpellier, France, and is a member of local health care clusters.

Contact: Philippe Outrebon (philippe@acobiom.com)

ACOBIDIOM

1682, rue de la Valsière - CS77394 - Cap Delta - Biopole Euromedecine II - 34184 Montpellier Cedex 4 - France
Tel.: +33 (0)467 419 748 - Fax: +33 (0)467 457 726 - Email: busdev@acobiom.com - Web: www.acobiom.com